Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab infusion duration and infusion reactions in rheumatoid arthritis
2011-002363-15Phase 2Completed
- Sponsor
- Roche
- Start
- Jun 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of tocilizumab in rheumatoid arthritis (RA) (2 arms), sponsored by Roche. Primary endpoint: Incidence of tocilizumab-related infusion reactions. Started Jun 2011; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2011-002363-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002363-15.